Prenatal and New-born Genetic Testing Market

Prenatal and New-born Genetic Testing Market (PCR, FISH, aCGH, NIPT and MSS) - Global Industry Analysis, Size, Share, Growth, Trends and Forecast 2013 - 2019

The presence of a seamless industry for prenatal care has given a thrust to the growth of the global prenatal and new-born genetic testing market. The rising incidence of prenatal complications has compelled medical practitioners to resort to prenatal testing procedures. Furthermore, advancements in sonography and other related technologies has also helped in creating a seamless fabric for medical testing across the globe. In this scenario, it is safe to expect that the global prenatal and new-born genetic testing market would grow at a boisterous pace in the times to follow. State approval of prenatal testing across several regional territories has created new opportunities for market growth.

  • Genetic testing has emerged as an important means to educate and inform expecting mothers about the possibility of genetic disorders in the baby. Furthermore, genetic testing is also useful for parents who exhibit a history of genetic disorders in their families.
  • The medical fraternity has become more liberal in its approach toward diagnosis and treatment. Prenatal testing is a part of the radical changes that have ensued across the medical industry. The total volume of revenues within the global prenatal and new-born genetic testing market is set to rise in the years to follow.
  • Use of new-born genetic testing for diagnosing the presence of down syndrome in infants is an important function in the medical industry. Medical experts are focusing on developing comprehensive training and education programs for parents of kids with genetic disorders. This move by the medical industry has led to increased use of prenatal and new-born genetic testing.
  • The rising incidence of dyslexia and down syndrome has given a thrust to market growth. The medical industry in Europe has acquired a remarkable level of maturity, and this factor shall play a crucial role in driving sales across the global prenatal and new-born genetic testing market.

Global Prenatal and New-born Genetic Testing Market: Snapshot

Prenatal and new-born genetic tests refer to the systematic diagnostic tests and screenings undertaken to determine the risk of certain genetic disorders in newborn children and fetuses in stages as early as eight to ten weeks of gestation. The use of a variety of screening and diagnostic tools for detecting chromosomal abnormalities and the risk of diseases such as Patau syndrome, Down syndrome, and Edward syndrome is increasing at a significant pace across the world.

The vast rise in prevalence of genetic abnormalities and late pregnancies are some of the key factors to have led to an increased demand for prenatal and new-born genetic tests across the globe. The vast advancements observed in diagnostic and screening technologies and the rise in awareness about genetic diseases are also considered crucial to the rising demand for genetic tests in children, both before and after birth. Transparency Market Research states that the market will exhibit a remarkable 26.9% CAGR over the report’s forecast period.

Diagnostic Techniques to Continue to Remain Preferred Option for Detecting Chromosomal Abnormalities

The prenatal and newborn genetic testing market can be broadly segmented into screening techniques and diagnostics techniques. Of these, the segment of diagnostic techniques, covering popular genetic testing methods such as fluorescence in-situ hybridization (FISH), array comparative genomic hybridization (aCGH), and polymerase chain reaction (PCR), accounts for a massive share of the market.

Diagnostic techniques are expected to retain their position as the leading contributor of revenue to the global prenatal and newborn genetic testing market over the forecast period, owing to their more effective and accurate results as compared to screening techniques. Of the key genetic diagnostic techniques available in the market, PCR techniques are expected to be the most preferred owing to their high efficiency and varied applications.

Of the key prenatal and newborn genetic screening techniques commonly used across the globe, including maternal serum screening (MSS) and non-invasive prenatal testing (NIPT), the segment of non-invasive prenatal testing is expected to lead the market for prenatal and newborn genetic screening techniques. This is owing to the fact that non-invasive screening techniques completely eliminate the risk of miscarriage associated with invasive tests such as Chorionic Villus Sampling (CVS) and amniocentesis.

Emerging Markets to Present Most Lucrative Growth Opportunities

Presently, North America is the dominant market for the global prenatal and newborn genetic testing market, accounting for a massive chunk of the overall market. Apart from a large pool of highly-aware parents and a rising prevalence of genetic disorders in the region, the large number of companies operating in the diagnostics as well as screening sectors have also helped the prenatal and newborn genetic testing market strengthen its foothold in the region. Another developed region, Europe, is also a mature market for prenatal and newborn genetic testing.

However, in the next few years, the prenatal and newborn genetic testing market will witness the most traction across emerging regional markets such as Asia Pacific, and Middle East and Africa. The vast untapped opportunities in these regions and an encouraging rise in awareness about genetic testing, rising affordability, and increasing prevalence of genetic diseases will together contribute towards the healthy growth of the prenatal and newborn genetic testing market in these regions in the near future.

Some of the key vendors operating in the diagnostics field of prenatal and newborn genetic testing are Ariosa Diagnostics, Bio-Rad Laboratories, Perkin Elmer, and Agilent Technologies. Key vendors operating in the screening segment of prenatal and newborn genetic testing are Verinata Health and Sequenom, Inc.

     
    Chapter 1 Introduction
    1.1 Report Description
    1.2 Market Segmentation
    1.3 Research Methodology
          1.3.1 Sources
    1.4 List of Abbreviations
     
    Chapter 2 Executive Summary
    2.1 Market Snapshot: Global Prenatal and Newborn Genetic Testing Market (2012 & 2019)
    2.2 Global Prenatal and Newborn Genetic Testing Market, by Segments, 2012 (USD Million)
     
    Chapter 3 Prenatal and Newborn Genetic Testing Market Overview
    3.1 Introduction and Market Definition
    3.2 Future Market Outlook
    3.3 Regulatory and Reimbursement Scenario for Prenatal and Newborn Screening
    3.4 Market Dynamics
          3.4.1 Drivers
          3.4.2 Restraints
          3.4.3 Market Opportunities
    3.5 Porter’s Five Forces Analysis: Global Prenatal and Newborn Genetic Testing Market
          3.5.1 Bargaining Power of Suppliers
          3.5.2 Bargaining Power of Buyers
          3.5.3 Threat of Substitutes
          3.5.4 Threat of New Entrants
          3.5.5 Competitive Rivalry
    3.6 Market Attractiveness Analysis
     
    Chapter 4 Prenatal and Newborn Genetic Testing Market, by Technology
    4.1 Overview
          4.1.1 Global Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 – 2019 (USD Million)
    4.2 Diagnostic Techniques
          4.2.1 Global Diagnostic Techniques Market Revenue, by Types, 2012 – 2019 (USD Million)
          4.2.2 Polymerase Chain Reaction (PCR)
          4.2.3 Fluorescence In-Situ Hybridization  (FISH)
          4.2.4 Array-Comparative Genomic Hybridization (aCGH)
    4.3 Screening Methods
          4.3.1 Global Screening Methods Market Revenue, by Types, 2012 – 2019 (USD Million)
          4.3.2 Non-invasive Prenatal Tests (MaterniT21 PLUS, Verifi, Harmony, Panorama, NIFTY, PrenaTest and Bambni Test)
          4.3.3 Maternal Serum Screening (MSS)
     
    Chapter 5 Prenatal and Newborn Genetic Testing Market, by Geography
    5.1 Overview
          5.1.1 Global Prenatal and Newborn Genetic Testing Market Revenue, by Geography2012 – 2019 (USD Million)
    5.2 North America
          5.2.1 North America Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
          5.2.2 North America Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
          5.2.3 North America Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
    5.3 Europe
          5.3.1 Europe Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
          5.3.2 Europe Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
          5.3.3 Europe Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
    5.4 Asia - Pacific
          5.4.1 Asia-Pacific Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
          5.4.2 Asia-Pacific Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
          5.4.3 Asia-Pacific Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
    5.5 Rest of the World (RoW)
          5.5.1 RoW Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
          5.5.2 RoW Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
          5.5.3 RoW Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
     
    Chapter 6 Competitive Landscape
    6.1 Market Share Analysis, by Key Players, 2012 (%)
     
    Chapter 7 Recommendations
    7.1 Market Strategy for Success
          7.1.1 Focus on forming alliances with diagnostic service providers in Asia-Pacific countries
          7.1.2 Emphasis on improving technology in order to increase accuracy, reduce the duration of result generation and price
    7.2 Barriers and Future Assumptions
          7.2.1 Lack of awareness about prenatal and newborn genetic testing in some Asian countries
          7.2.2 Regulatory compliance and ethical issues
     
    Chapter 8 Company Profiles
    8.1 Agilent Technologies, Inc.
          8.1.1 Company Overview
          8.1.2 Financial Overview
          8.1.3 Product Portfolio
          8.1.4 Business Strategies
          8.1.5 Recent Developments
    8.2 Ariosa Diagnostics, Inc.
          8.2.1 Company Overview
          8.2.2 Financial Overview
          8.2.3 Product Portfolio
          8.2.4 Business Strategies
          8.2.5 Recent Developments
    8.3 Bio-Rad Laboratories, Inc.
          8.3.1 Company Overview
          8.3.2 Financial Overview
          8.3.3 Product Portfolio
          8.3.4 Business Strategies
          8.3.5 Recent Developments
    8.4 Illumina, Inc.
          8.4.1 Company Overview
          8.4.2 Financial Performance
          8.4.3 Product Portfolio
          8.4.4 Business Strategies
          8.4.5 Recent Developments
    8.5 Laboratory Corporation of America Holdings (LabCorp)
          8.5.1 Company Overview
          8.5.2 Financial Overview
          8.5.3 Product Portfolio
          8.5.4 Business Strategies
          8.5.5 Recent Developments
    8.6 Natera, Inc.
          8.6.1 Company Overview
          8.6.2 Financial Overview
          8.6.3 Product Portfolio
          8.6.4 Business Strategies
          8.6.5 Recent Developments
    8.7 PerkinElmer, Inc.
          8.7.1 Company Overview
          8.7.2 Financial Overview
          8.7.3 Product Portfolio
          8.7.4 Business Strategies
          8.7.5 Recent Developments
    8.8 Sequenom, Inc.
          8.8.1 Company Overview
          8.8.2 Financial Overview
          8.8.3 Product Portfolio
          8.8.4 Business Strategies
          8.8.5 Recent Developments
    List of Tables
     
    TABLE 1 Market Snapshot: Global Prenatal and Newborn Genetic Testing Market (2012 & 2019)
    TABLE 2 Technological Approach for Non-Invasive Prenatal Screening Tests
    TABLE 3 Global Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 – 2019 (USD Million)
    TABLE 4 Global Diagnostic Techniques Market Revenue, by Types, 2012 – 2019 (USD Million)
    TABLE 5 Global Screening Methods Market Revenue, by Types, 2012 – 2019 (USD Million)
    TABLE 6 Global Prenatal and Newborn Genetic Testing Market Revenue, by Geography, 2012 – 2019 (USD Million)
    TABLE 7 North America Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
    TABLE 8 North America Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
    TABLE 9 North America Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
    TABLE 10 Europe Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
    TABLE 11 Europe Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
    TABLE 12 Europe Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
    TABLE 13 Asia-Pacific Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
    TABLE 14 Asia-Pacific Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
    TABLE 15 Asia-Pacific Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)
    TABLE 16 RoW Prenatal and Newborn Genetic Testing Market Revenue, by Technology, 2012 - 2019 (USD Million)
    TABLE 17 RoW Diagnostic Techniques Market Revenue, by Types, 2012 - 2019 (USD Million)
    TABLE 18 RoW Screening Methods Market Revenue, by Types, 2012 - 2019 (USD Million)

    List of Figures

     

    FIG. 1 Prenatal and Newborn Genetic Testing: Market Segmentation

    FIG. 2 Global Prenatal and Newborn Genetic Testing Market, by Segments, 2012 (USD Million)

    FIG. 3 Adoption Curve Analysis for Genetic Testing Market

    FIG. 4 Porter’s Five Forces Analysis: Global Prenatal and Newborn Genetic Testing Market

    FIG. 5 Market Attractiveness Analysis: Global Prenatal and Newborn Genetic Testing Market, 2012

    FIG. 6 Global PCR Market Revenue, 2012 – 2019 (USD Million)

    FIG. 7 FISH Procedural Steps

    FIG. 8 Global FISH Market Revenue, 2012 – 2019 (USD Million)

    FIG. 9 Global aCGH Market Revenue, 2012 – 2019 (USD Million)

    FIG. 10 Global NIPT Market Revenue, 2012 – 2019 (USD Million)

    FIG. 11 Global MSS Market Revenue, 2012 – 2019 (USD Million)

    FIG. 12 Global Prenatal and Newborn Genetic Testing: Market Share, by Key Players, 2012 (%)

    FIG. 13 Annual Sales: Agilent Technologies, Inc., 2010 – 2012 (USD Million)

    FIG. 14 Annual Sales: Bio-Rad Laboratories, Inc., Clinical Diagnostics Segment, 2010 – 2012 (USD Million)

    FIG. 15 Annual Sales: Illumina, Inc., 2010 – 2012 (USD million)

    FIG. 16 Annual Sales: LabCorp, 2010– 2012 (USD Million)

    FIG. 17 Annual Sales: PerkinElmer, Inc. (Human Health Segment), 2010 – 2012 (USD Million)

    FIG. 18 Annual Sales: Sequenom Inc., 2010–2012 (USD Million)

Copyright © Transparency Market Research, Inc. All Rights reserved